• Digestive discomfort: Bloating, cramping, abdominal pain or a general sense of digestive unease.
• Irregular bowel habits: Constipation, loose stools, urgency or fluctuating stool patterns.
• Signs of inflammation: Abdominal tenderness, gut sensitivity or changes in stool linked with suspected inflammation.
• Suspected digestive infections: Diarrhoea, nausea or vomiting that may occur with acute or persistent digestive upset.
• Food-related symptoms: Fullness, nausea or discomfort after certain foods.
• Low energy or fatigue: Tiredness that may accompany digestive imbalance.
• Skin or joint concerns: Rashes, irritation, joint aches or stiffness that occur alongside gut symptoms.
• After travel or exposure: Changes in digestion, stool patterns or comfort following recent travel.
• Post-antibiotic changes: Noticeable shifts in stool regularity or comfort after antibiotic use.
• Blood in stool: Visible or suspected blood in stool (requires medical review).
• Related conditions: Situations where conditions such as IBS, IBD, malabsorption or suspected dysbiosis may prompt a detailed stool assessment.

GI360 Complete x 2 Days provides an in-depth assessment of gastrointestinal health by combining multiplex PCR technology, growth-based culture, MALDI-TOF identification, biochemical assays and microscopy. This comprehensive approach evaluates digestion, inflammation, microbial balance, parasitology, viral detection and overall microbiome diversity across a two-day stool collection to build a robust overview of gastrointestinal function.

The profile may be clinically useful when exploring symptoms such as abdominal discomfort, stool changes, bloating, diarrhoea, nausea, fatigue or food-related reactions. By analysing bacterial phyla, pathogenic organisms, digestive and inflammatory markers, short-chain fatty acids, beta-glucuronidase, yeast, parasites and viral targets, the GI360 helps illustrate how microbial composition and digestive efficiency may relate to presenting symptoms. The Dysbiosis Index provides additional context by comparing microbial patterns to a reference population.

GI360 Complete x 2 Days offers a multi-method evaluation of the gut ecosystem, integrating culture, PCR, microscopy and biochemical data into a single report. The extended two-day collection enhances representation of microbial and parasitology findings, supporting interpretation of digestive capacity, microbial stability, inflammatory activity and wider gastrointestinal function.

Practical (add-ons available)

Specimen requirements: STOOL

2 day collection

Also available as 1 and 3 day collection

QUANTITY: Each vial must be filled until the indicated fill line, and must not be filled to the top.

STORAGE: 

Black & Orange capped vials: REFRIGERATE (DO NOT freeze)

White capped vial: FREEZE for at least 6 hours

PLEASE NOTE:

If there are any missing or improperly produced samples, the following options are available:

1. SEND A NEW (COMPLETE) SAMPLE, where the patient/practitioner will be liable for the added shipment costs.

2. REQUEST a downgraded version of the test. The downgraded report will only contain the analytes measured from each vile:

   - BLACK capped vial: parasitology

   - YELLOW/ORANGE capped vial: Bacteria/Yeast Culture & PCR

   - WHITE capped vial: all stool chemistries (acetate, butyrate, calprotectin, elastase, fat stain, lactoferrin, lysozyme, mucus, muscle fibres, occult blood, pH, propionate, RBC, SIgA, valerate, vegetable fibres, WBC and beta-glucuronidase.

Once the downgraded version of the test has been requested based on the delivered vials, the invoice price will be adjusted to accommodate the new report. A new order will have to be submitted to receive a full report, as results cannot be transferred between past orders.

No Call / Inhibited
In certain circumstances, stool samples may not yield results for a limited section of viruses, pathogenic bacteria and parasites [known as : No Call / Inhibited]. Statistically this can affect approximately 6% of tests.
Many factors contribute to this issue including diet, medication, supplements, and competing DNA. Excessive calcium, tannic acid, bile salts, haemoglobin, melanin, collagen, urea, degradation products, complex polysaccharides and polyphenolic substances have also been found to cause inhibition.Test reports affected are not considered to be defective and thus are not eligible for cancellation or refunds.
Resubmission of the a supplementary sample to attempt analysis can be accommodated with billable costs limited to supply and return shipping.
By ordering this test, you accept the conditions and risks explained here.

Average processing time:

21 days

Available add-ons:

Zonulin add-on for GI360

Age Considerations:

The PCR Microbiome section (only) may best be served for those ages 2 and above due to variations in the microbiome in ages 0-2. For infants and new-borns, collect from the middle of the stool, not touching the diaper as this will contaminate the sample. The stool needs to be free of urine.

Research

• Aasbrenn M, Valeur J, Farup PG. Evaluation of a faecal dysbiosis test for irritable bowel syndrome in subjects with and without obesity. Scandinavian Journal of Clinical and Laboratory Investigation. 2017;78(1-2):109-113. DOI: 10.1080/00365513.2017.1419372

• Andréasson K, Alrawi Z, Persson A, Jönsson G, Marsal J. Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease. Arthritis Research & Therapy. 2016;18(1). DOI: 10.1186/s13075-016-1182-z

• Bennet SMP, Böhn L, Störsrud S, et al. Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. Gut. 2017;67(5):872-881. DOI: 10.1136/gutjnl-2016-313128

• Casén C, Vebø HC, Sekelja M, et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Alimentary Pharmacology & Therapeutics. 2015;42(1):71-83. DOI: 10.1111/apt.13236

• Farup PG, Aasbrenn M, Valeur J. Separating “good” from “bad” faecal dysbiosis – evidence from two cross-sectional studies. BMC Obesity. 2018;5(1). DOI: 10.1186/s40608-018-0207-3

• Farup P, Valeur J. Faecal Microbial Markers and Psychobiological Disorders in Subjects with Morbid Obesity. A Cross-Sectional Study. Behavioral Sciences. 2018;8(10):89. DOI: 10.3390/bs8100089

• Magnusson MK, Strid H, Sapnara M, et al. Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition. Journal of Crohns and Colitis. 2016;10(8):943-952. DOI: 10.1093/ecco-jcc/jjw051

• Magnusson MK, Strid H, Isaksson S, Simrén M, Öhman L. The Mucosal Antibacterial Response Profile and Fecal Microbiota Composition Are Linked to the Disease Course in Patients with Newly Diagnosed Ulcerative Colitis. Inflammatory Bowel Diseases. 2017;23(6):956-966. DOI: 10.1097/mib.0000000000001130

• Mazzawi T, Lied GA, Sangnes DA, et al. The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. Plos One. 2018;13(11). DOI: 10.1371/journal.pone.0194904

• Olbjørn C, Småstuen MC, Thiis-Evensen E, et al. Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease – associations with disease phenotype, treatment, and outcome. Clinical and Experimental Gastroenterology. 2019;Volume 12:37-49. DOI: 10.2147/ceg.s186235

• Thorkildsen LT, Nwosu FC, Avershina E, et al. Dominant Fecal Microbiota in Newly Diagnosed Untreated Inflammatory Bowel Disease Patients. Gastroenterology Research and Practice. 2013;2013:1-13. DOI: 10.1155/2013/636785

• Valeur J, Småstuen MC, Knudsen T, Lied GA, Røseth AG. Exploring Gut Microbiota Composition as an Indicator of Clinical Response to Dietary FODMAP Restriction in Patients with Irritable Bowel Syndrome. Digestive Diseases and Sciences. 2018;63(2):429-436. DOI: 10.1007/s10620-017-4893-3

• Vebø HC, Sekelja M, Nestestog R, et al. Temporal Development of the Infant Gut Microbiota in Immunoglobulin E-Sensitized and Nonsensitized Children Determined by the GA-Map Infant Array. Clinical and Vaccine Immunology. 2011;18(8):1326-1335. DOI: 10.1128/cvi.00062-11